228株鲍曼不动杆菌感染的临床分布和耐药性分析

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (32 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the clinical infection and drug resistance of Acinetobacter baumannii in order to provide a theoretical basis for clinical rational drug use.Methods A total of 228 strains of Acinetobacter baumannii isolated of hospitalized patients from January 2015 to December 2017 were selected for study.Vitek 2 compact automatic microbial identification and analysis system was used to identify strains,The specimens,distribution of departments,and drug resistance of Acinetobacter baumannii were analyzed.All data were statistically analyzed using WHONET5.4,a drug resistance monitoring software.Results A total of 228 strains of Acinetobacter baumannii were isolated.The detection rate was high in sputum specimens,wound secretions and urine,there were 154 strains accounted for 67.54%,31 strains for 13.60%,and 14 strains for 6.14%.In the distribution of the department,there were 108(47.37%)strains in the intensive care unit,followed by 36 (15.79%)strains in the respiratory medicine department.Acinetobacter baumannii had the lowest drug resistance to Minocycline and Cefoperazone/Sulbactam,but for other antimicrobial agents,the drug resistance rate was over 60%.Conclusion The detection rate of Acinetobacter baumannii is high,and the drug resistance is increasing year by year.It should be highly noted that standard continuous monitoring of Acinetobacter baumannii and the analysis of its drug resistance are performed.

Key words： Acinetobacter baumannii Antibacterial agent Drug resistance Nosocomial infection

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Po

Cite this article:

WANG Po. Analysis of clinical distribution and drug resistance of Acinetobacter baumannii infection in 228 strains[J]. 中国当代医药, 2018, 25(27): 129-131.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I27/129

[1]	Badave GK，Kulkarni D.Biofilm producing multidrug resistant Acinetobacter baumannii：an emerging challenge[J].J Clin Diagn Res.2015，9（1）：DC8-DC10.
[2]	马序竹，吕媛.鲍曼不动杆菌对主要抗菌药物耐药机制[J].中国临床药理学杂志，2009，25（1）：90-94.
[3]	廖娟，方凤，林如风.261株鲍曼不动杆菌临床分布及耐药性分析[J].实验与检验医学，2015，33（2）：165-167.
[4]	周庭银.临床微生物检验标准化操作[M].第2版.上海：上海科学技术出版社，2010：263.
[5]	周燕飞，邓敏.连续3年临床分离鲍曼不动杆菌临床分布及耐药性[J].中国感染控制杂志，2015，14（1）：42-44.
[6]	徐倩，郭卫真，刘玥.579株鲍曼不动杆菌的临床分布及耐药性分析[J].国际检验医学杂志，2014，35（23）：3226-3227.
[7]	张华，贾宁.鲍曼不动杆菌耐药性诊断分析[J].中国实验诊断学，2015，19（1）：20-22.
[8]	邓健康，郭晓兰.1685株鲍曼不动杆菌的临床分布及耐药性研究[J].检验医学与临床，2016，13（3）：304-306.
[9]	Pogue JM，Mann T，Barber KE，et al.Carbapenem-resistant Acinetobacterbaumannii：epidemiology，surveillance and management[J].Expert Rev Anti Infect Ther，2013，11（4）：383-393.
[10]	朱晓华，汪涛.鲍曼不动杆菌的耐药机制及防治[J].检验医学与临床，2010，7（13）：1393-1395.
[11]	胡付品，朱德妹，汪复，等.2011年中国CHINET细菌耐药性监测[J].中国感染与化疗杂志，2012，12（5）：321-329.
[12]	汪复，朱德妹，胡付品，等.2012年中国CHINET细菌耐药性监测[J].中国感染与化疗杂志，2013，13（5）：321-330.
[13]	胡付品，朱德妹，汪复，等.2013年中国CHINET细菌耐药性监测[J].中国感染与化疗杂志，2014，14（5）：365-374.
[14]	张鹏，周燕斌，黄炎明.多重耐药鲍曼不动杆菌耐药机制及治疗策略的研究进展[J].中国医药科学，2014，4（14）：26-29，43.
[15]	Eugenin EA.Community-acquired pneumonia infections by Acinetobacter baumannii：how does alcohol impact the antimicrobial functions of macrophages?[J].Virulence.2013，4（6）：435-436.